No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Teanx Therapeutics Plans Secondary Offering
Tenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
Tenax Therapeutics | 10-K: FY2024 Annual Report
Tenax Therapeutics | 8-K: Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Tenax Therapeutics Q4 2024 GAAP EPS $(0.18) Beats $(0.42) Estimate
Tenax Therapeutics Completed Private Placements With Proceeds of About $125 M to Support Studies for TNX-103, Fund Ops Through 2027 >TENX